PACB
Pacific Biosciences of California
2.50$
+1.2%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -84.9% | -51.6% | -74.9% | -72.2% | -84.5% | -86.2% | 24.7% | -85.2% | -205.1% | -132.9% | -133.8% | -69.5% | |
| 7.0% | 4.0% | 4.3% | 9.0% | 9.2% | 10.9% | 11.8% | 8.9% | 13.5% | 16.3% | 34.6% | 241.5% | |
| 16.4% | 14.9% | 21.6% | 21.8% | 29.4% | 18.0% | 22.2% | 61.9% | 61.3% | 36.0% | 46.1% | 26.0% | |
| 17.2% | 14.7% | 21.4% | 22.5% | 29.2% | -1.6% | -20.9% | 28.3% | 67.8% | – | – | – | |
| -1.3% | -33.8% | -19.8% | -6.4% | 7.2% | -3.3% | -3.5% | 16.1% | -42.1% | -29.4% | -26.3% | 2.8% | |
| 2.7% | 3.2% | 9.0% | 11.2% | 2.4% | 3.1% | 1.3% | 4.5% | 13.2% | 4.4% | 4.0% | 1.7% | |
| 32.3% | 9.3% | -16.4% | -1.7% | -48.9% | 68.3% | -278.0% | -519.9% | 90.5% | 2.3% | 80.5% | 72.2% | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| 69.3% | 39.3% | 72.7% | 78.4% | 136.3% | 9.4% | 296.4% | 250.3% | – | – | – | – | |
| -7.4% | -4.9% | -5.0% | -4.8% | -20.3% | -17.6% | -20.3% | 685.9% | -1.3% | -0.9% | -0.3% | 0.0% | |
| 69.3% | 39.3% | 72.7% | 73.6% | 136.3% | 29.2% | 319.2% | 896.1% | 7.5% | 58.0% | -27.9% | 2.1% | |
| 16.6% | -3.0% | -18.6% | -0.3% | 3.0% | 11.3% | 65.9% | 291.1% | -107.2% | -72.4% | -80.6% | 4.8% | |
| -87.6% | -54.9% | -83.9% | -83.4% | -86.8% | -89.3% | 23.4% | -89.7% | -218.3% | -137.3% | -137.8% | -71.2% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.